(L)-cyclohexylalanine methyl ester hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (L)-cyclohexylalanine methyl ester hydrochloride
• 英文别名: methyl (S)-2-(cyclohexylamino)propanoate hydrochloride；(S)-cyclohexylalanine methyl ester hydrochloride；(2S)-Cyclohexylalanine methyl ester, hydrochloride salt；Cyclohexylalanine methyl ester hydrochloride salt；cyclohexyl-L-alanine methyl ester hydrochloride；(S)-(-)-Cyclohexylalanine methyl ester hydrochloride；methyl (2S)-2-(cyclohexylamino)propanoate;hydrochloride
• 化学式: C₁₀H₁₉NO₂*ClH
• 分子量: 221.727
• InChiKey: PYBRIESQJNDAMI-QRPNPIFTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.89
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (L)-cyclohexylalanine methyl ester hydrochloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以29%的产率得到N-(4-Methylpiperazin-1-yl-sulfonyl)-Cyclohexylalanine
  参考文献：
  名称：

  Endothelin converting enzyme inhibitors

  摘要：

  抑制内皮素转化酶的化合物已被披露。这些化合物可用于治疗高血压、充血性心力衰竭、心肌梗死、再灌注损伤、冠状动脉狭窄、脑血管痉挛、急性肾衰竭、非甾体抗炎药诱导的胃溃疡、环孢霉素诱导的肾毒性、内毒素诱导的毒性、哮喘和动脉粥样硬化。

  公开号：

  US05338726A1
• 作为产物：
  描述：

  L-丙氨酸甲酯盐酸盐 、 环己酮 在 N-甲基吗啉 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、400.01 kPa 条件下， 反应 12.0h， 以95%的产率得到(L)-cyclohexylalanine methyl ester hydrochloride
  参考文献：
  名称：

  新型（S）-1,6-二烷基哌嗪-2,5-二酮和（3 S，6 S）-1,3,6-三烷基哌嗪-2,5-二酮的合成与结构

  摘要：

  从相应的（S）分三步制备11个（S）-1,6-二烷基哌嗪-2,5-二酮和五个（3 S，6 S）-1,3,6-三烷基哌嗪-2,5-二酮-α-氨基酸酯，包括还原性N-烷基化，N-酰化和环化。（S）-1,6-二烷基哌嗪-2,5-二酮的合成具有广阔的范围，可以制备在N（1）上具有伯烷基和仲烷基的二酮哌嗪，而合成（3 S，6 S）-1,3,6-三烷基哌嗪-2,5-二酮仅限于在N（1）具有伯烷基的化合物。在羰基化合物的存在下，通过催化氢化对氨基酸酯盐酸盐进行还原性烷基化被证明是制备稳定的（可储存的）α-烷基氨基酸酯盐酸盐的一种简单，有效和通用的方法。通过NMR和X射线衍射确定新化合物的结构。

  DOI：

  10.1016/j.tetasy.2011.03.014

文献信息

• Benzoxazepinones and their use as squalene synthase inhibitors
  申请人：——

  公开号：US20030078251A1

  公开（公告）日：2003-04-24

  There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

  披露了一种由公式[I]表示的化合物： 1 其中R 1 是可选地取代的1-羧乙基，可选地取代的烷基亚磺酰基，可选地取代的(羧基环烷基)-烷基，—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基，X 2 和X 3 是键，—O—，—S—，Ar是二价芳香族等)，R 2 是可选地由酰氧基和/或羟基取代的烷基，R 3 是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性，用于预防或治疗高脂血症。
• [EN] AMINO ACID DEPLETION AGENTS AS ANTIPROLIFERATIVE AGENTS<br/>[FR] AGENTS D'APPAUVRISSEMENT EN ACIDES AMINÉS EN GUISE D'AGENTS ANTIPROLIFÉRATIFS
  申请人：UNIV CENTRAL FLORIDA RES FOUND INC

  公开号：WO2020047361A1

  公开（公告）日：2020-03-05

  Novel compounds are described which decrease the intracellular levels of leucine and methionine. Treatment with these amino acid depletion agents affects many metabolic and life processes which rely upon methionine, leucine and their derivatives. Methionine depletion not only inhibits protein synthesis, but also polyamine biosynthesis and significantly reduces intracellular pools of the native polyamines, spermidine and spermine. Since methionine restriction has been shown to mimic caloric restriction in life extension studies across multiple species, these compounds are also expected to extend lifespan by limiting methionine supply.

  描述了几种新的化合物，这些化合物能够降低细胞内亮氨酸和蛋氨酸的水平。使用这些氨基酸剥夺剂影响许多依赖蛋氨酸、亮氨酸及其衍生物的代谢和生命过程。蛋氨酸剥夺不仅抑制蛋白质合成，还抑制聚胺生物合成，并显著减少细胞内天然聚胺，即亚精胺和精胺的池。由于蛋氨酸限制在多个物种的生命延长研究中已被证明可以模仿卡路里限制，因此预计这些化合物通过限制蛋氨酸供应也能延长寿命。
• [EN] PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES PEPTIDIQUES EN TANT QU'INHIBITEURS DE LA PROTEASE A CYSTEINE
  申请人：AXYS PHARM INC

  公开号：WO2004000838A1

  公开（公告）日：2003-12-31

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是卡特普辛B、K、L、F和S，因此在治疗由这些蛋白酶介导的疾病方面具有用途。本发明涉及包含这些化合物的药物组合物以及制备它们的方法。
• [EN] AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES AMIDINO SERVANT D'INHIBITEURS DE PROTEASES A CYSTEINE
  申请人：AXYS PHARMACEUTICALS

  公开号：WO2004108661A1

  公开（公告）日：2004-12-16

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是包括B、K、L、F和S半胱氨酸蛋白酶，因此在治疗由这些蛋白酶介导的疾病方面具有用处。本发明涉及包含这些化合物的药物组合物以及其制备方法。
• Acyl compounds
  申请人：Ciba-Geigy Corp

  公开号：US05399578A1

  公开（公告）日：1995-03-21

  Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.

  式为##STR1##的化合物，其中R.sub.1是未取代或取代为卤素或羟基的脂肪烃基，或者是环脂烃或芳基脂肪烃基；X.sub.1是CO、SO.sub.2或--O--C(.dbd.O)--，其中羰基的碳原子连接到式I中显示的氮原子；X.sub.2是未取代或取代为羟基、羧基、氨基、胍基或环脂烃或芳香基的二价脂肪烃基，或者是二价环脂烃脂肪烃基，脂肪烃基的碳原子还可以通过另一个二价脂肪烃基进行桥接；R.sub.2是羧基，如果需要，可以酯化或酰胺化，取代或未取代的氨基，甲酰基，如果需要，可以缩醛化，1H-四唑-5-基，吡啶基，羟基，如果需要，可以醚化，S(O).sub.m --R，其中m为0、1或2，R为氢或脂肪烃基，烷酰基，未取代或N-取代的磺酰胺基或PO.sub.n H.sub.2，其中n为2或3；X.sub.3是二价脂肪烃基；R.sub.3是羧基，5-四唑基，SO.sub.3 H，PO.sub.2 H.sub.2，PO.sub.3 H.sub.2或卤代烷基磺酰胺基；环A和B彼此独立地被取代或未取代；以自由形式或盐形式，可以按已知方法制备，并可用作药物活性成分。